Literature DB >> 12893070

Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China.

Wei Zhang1, LiFeng Wang, Andrea Chang, YuSheng Jin, JianYu Rao.   

Abstract

Increased cyclooxygenase-2 (COX-2) expression has been observed in both squamous cell carcinoma (SCC) and adenocarcinoma (AC) in Western countries, and COX-2 inhibitors have been considered as potential chemopreventive agents for esophageal cancers. Since chemoprevention often targets the premalignant lesions in high-risk population, it is worthwhile to study COX-2 expression in a spectrum of premalignant and malignant lesions obtained from the high-risk populations. In this study, biopsy samples were taken from 240 subjects identified by screening of the high-risk population in Cixian, China, including 27 normal, 29 with squamous hyperplasia, 84 with dysplasia (31 low grade and 53 high grade), 30 with carcinoma in situ, and 70 with invasive carcinoma (60 SCC and 10 AC). For comparison, tissue samples were also collected from He Lon Jiang Province, a low-risk population in China, including 10 patients with invasive SCC, 20 patients with AC, and 17 patients with Barrett's esophagus. The COX-2 protein expression was examined by immunohistochemistry. Using 10% staining as a threshold, 9 of 10 (90%) invasive SCC from low-risk population were COX-2 positive. However, no positive COX-2 staining was seen on normal, hyperplastic, dysplastic, and in situ squamous lesions from the high-risk population, and only 4 of 60 (6%) invasive SCC exhibited positive COX-2 staining. For glandular lesions, 6 of 10 (60%) AC from high-risk area and 15 of 20 (75%) from low-risk area showed positive COX-2 staining, and 12 of 17 (70%) premalignant Barrett's esophagus were also positive. Our findings show that COX-2 expression various in squamous lesions from high- and low-risk areas, but not in glandular lesions. Additional studies are needed to fully explore the mechanisms that are associated with the different COX-2 immunohistochemical staining patterns in esophageal squamous lesions from low- and high-risk populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893070     DOI: 10.1016/s0361-090x(03)00072-2

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  5 in total

1.  Randomized phase II trial of lyophilized strawberries in patients with dysplastic precancerous lesions of the esophagus.

Authors:  Tong Chen; Fei Yan; Jiaming Qian; Mingzhou Guo; Hongbing Zhang; Xiaofei Tang; Fang Chen; Gary D Stoner; Xiaomin Wang
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-01

2.  Molecular Marker Expression Is Highly Heterogeneous in Esophageal Adenocarcinoma and Does Not Predict a Response to Neoadjuvant Therapy.

Authors:  Nathan W Bronson; Brian S Diggs; Gene Bakis; Kenneth M Gatter; Brett C Sheppard; John G Hunter; James P Dolan
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452

Review 3.  Squamous intraepithelial neoplasia of the esophagus: past, present, and future.

Authors:  Michio Shimizu; Koji Nagata; Hiroshi Yamaguchi; Hiroto Kita
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

4.  Cyclooxygenase-2, a Potential Therapeutic Target, Is Regulated by miR-101 in Esophageal Squamous Cell Carcinoma.

Authors:  Ying Shao; Peng Li; Sheng-tao Zhu; Ji-ping Yue; Xiao-jun Ji; Zhen He; Dan Ma; Li Wang; Yong-jun Wang; Ye Zong; Yong-dong Wu; Shu-tian Zhang
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

5.  MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.

Authors:  Ying Shao; Peng Li; Sheng-Tao Zhu; Ji-Ping Yue; Xiao-Jun Ji; Dan Ma; Li Wang; Yong-Jun Wang; Ye Zong; Yong-Dong Wu; Shu-Tian Zhang
Journal:  Oncotarget       Date:  2016-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.